retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 GLP3 – Reta (10mg) |

If it appears and persists, one option is to reduce the dose or stop use and consult a healthcare professional, especially if it is being taken for a clinical reason

Overall, the pattern suggests that inter-individual variability in composite redox indices, particularly glutathione-based measures, may statistically co-vary with changes in selected functional measures in physically active older adults, but confirmation in larger, adequately powered samples specifically designed to test these relationships is required

Reversal at this scale is clinically significant and is not a side effect of the weight loss alone

Am J Physiol 251(6 Pt 2):H1106H1110

In light of this information, NCL offers this advice to consumers when considering GLP-1 treatment options: Before seeking treatment with a GLP-1 drug, talk to your doctor or health provider to determine if you are a candidate for treatment based on your risk factors and degree of obesity